Retrospective Analysis of COVID-19 Vaccination in a University Hospital and the Relationship with the Epidemic Rate

Işıl Deniz Alıravcı; Fatma Gümüşer; Alper Şener

doi:10.33533/jpm.v16i2.4818

Authors

Işıl Deniz Alıravcı Department of Infectious Diseases and Clinical Microbiology,Health Practice and Reseaech Hospital, Çanakkale 18 Mart University, Çanakkale http://orcid.org/0000-0002-4740-1579
Fatma Gümüşer Department of Infectious Diseases and Clinical Microbiology, Kahramanmaraş Sütçü İmam University, Kahramanmaraş http://orcid.org/0000-0003-1103-4962
Alper Şener Department of Infectious Diseases and Clinical Microbiology, Atatürk Training and Research Hospital, İzmir Katip Çelebi University, İzmir http://orcid.org/0000-0003-2774-8601

DOI:

https://doi.org/10.33533/jpm.v16i2.4818

Keywords:

Adult, epidemiology, vaccine

Abstract

It was aimed to make a retrospective analysis of the vaccines administered in the vaccine unit of our hospital since the beginning of the COVID-19 pandemic. The study was carried out retrospectively from the vaccination records our hospital, 14 January 2021 to 01 July 2022. In the 18-month period, a total of 75079 (100%) vaccines were administered, 59386 (79%) were Biontech and 15693 (21%) were Sinovac vaccines. Only Sinovac was available until June, therefore, 66% of the Sinovac vaccines were administered in the first five months period. After the Biontech vaccine started to be applied in our hospital, the rates of Sinovac vaccination have declined drastically. When the epidemic and vaccination graphs were examined separately, inverse correlation was found between the peak points of the epidemic and vaccine graphics. Biontech was found to be the most preferred vaccine by individuals against COVID-19 in this study.

References

Weekly epidemiological update on COVID-19, 20 July 2022 (Internet). World Health Organization (WHO) (Access 20 July 2022). Available from

https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid19

Tracking Coronavirus vaccitanions araound the World (Internet). (Access 20 July 2022). Available from

https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html

Science Brief: COVID-19 vaccines and vaccination (Internet). Centers for disease control and prevention (CDC), (Access 20 July 2022). Available from

https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fullyvaccinated-people.htm

Yap C, Ali A, Prabhakar A, Prabhakar A, Pal A, Lim YY, et al. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Ther Adv Vaccines Immunother. 2021;(9):1-21.

Palacios R, Patino EG, Piorelli R de O, Conde MTRP, Batista AP, Zeng G, et al. Double-blind, randomized, placebo-cntrolled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) Vaccine manifactured by Sinovac- PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(853):1-3.

Dagan N, Barda N, E Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.

Genel Koronavirüs tablosu (Internet). ) (Access 20 July 2022).Available from

https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html

Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of nRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an abservational study using national surveiilance data. Lancet. 2021;(397):1819-29.

Paternina-Caicedo A, Jit M, Alvis-Guzman N, Fernandez JC, Hernandez J, Poz-Wilches JJ, et al. Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. Lancet Reg Health Am. 2022;(12):1-9.

Akpolat T, Uzun O. Reduced mortality rate after coronavac vaccine among healtcare workers. J Infect. 2021;(83):750-2.

Uzun O, Akpolat T, Varol A, Turan S, Gokbulut-Bektas S, Cetinkaya PD, et al. COVID-19: Vaccination vs.hospitalization. Infection. 2022;(50):747-52.

Aw J, Seng JJB, Seah SSY, Low LL. COVID-19 vaccine hesitancy-a scoping review of literature in high-income countries. Vaccines. 2021;(9):900.

Chariyalertsak S, Intawong K, Chalom K, Wonghirundecha T, Thangprachum A, Chatirosniramit N, et al. Effectiveness of heterologous 3rd and 4th dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand. Research Square. 2022;1-15.

Voysey M, Clemens SAC, Madhi SA, Weck LY, Falegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;(397):99–111.

Köse E, Otura G, Ekerbiçer HÇ, Arslan A, Özaygın A, Nas B, Yavuz B, et al. Investigation of descriptive characteristics of randomized controlled trials of COVID-19 vaccines. Van Tıp Derg. 2022;29(1):76-83.

Mayr FB, Talisa VB,Shaikh O, Yende Sachin, Butt AA. Effectiveness of homologous or heterologous Covid-19 boosters in veterans. N Engl J Med. 2022;(386):1375-7.

Accorsi EK, Britton A, Shang N, Fleming-Dutra KE, Link-Gelles R, Smith ZR, Denado G,et al. Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron. N Engl J Med. 2022;386(25):2433-5.

Jing You, Nagma Shaik, Haihua Chen. ASIS⅋Annual Meeting 2021. Salt Lake City, UT.